EyePoint Pharmaceuticals, Inc. Forecast, price target & analysts
EyePoint Pharmaceuticals, Inc. Target price 2025 - Analyst rating & recommendation
EyePoint Pharmaceuticals, Inc. Classifications & Recommendation:
EyePoint Pharmaceuticals, Inc. Price Target
| Target Price | $27.54 |
| Price | $9.64 |
| Potential |
185.69%
register free of charge
|
| Number of Estimates | 14 |
|
14 Analysts have issued a price target EyePoint Pharmaceuticals, Inc. 2026 .
The average EyePoint Pharmaceuticals, Inc. target price is $27.54.
This is
185.69%
register free of charge
$71.40
640.66%
register free of charge
$18.18
88.59%
register free of charge
|
|
| A rating was issued by 19 analysts: 18 Analysts recommend EyePoint Pharmaceuticals, Inc. to buy, 1 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the EyePoint Pharmaceuticals, Inc. stock has an average upside potential 2026 of
185.69%
register free of charge
|
Sales and Margin forecast 2025, 2026 to 2032
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Million $ | 43.27 | 41.57 |
| 5.98% | 3.94% | |
| EBITDA Margin | -333.51% | 655.21% |
| 104.45% | 296.46% | |
| Net Margin | -302.45% | -492.94% |
| 96.59% | 62.98% |
14 Analysts have issued a sales forecast EyePoint Pharmaceuticals, Inc. 2025 . The average EyePoint Pharmaceuticals, Inc. sales estimate is
This results in the following potential growth metrics:
4 Analysts have issued an EyePoint Pharmaceuticals, Inc. EBITDA forecast 2025. The average EyePoint Pharmaceuticals, Inc. EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
14 EyePoint Pharmaceuticals, Inc. Analysts have issued a net profit forecast 2025. The average EyePoint Pharmaceuticals, Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2032
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -2.32 | -2.98 |
| 27.47% | 28.45% | |
| P/E | negative | |
| EV/Sales | 8.30 |
14 Analysts have issued a EyePoint Pharmaceuticals, Inc. forecast for earnings per share. The average EyePoint Pharmaceuticals, Inc. EPS is
This results in the following potential growth metrics and future valuations:
EyePoint Pharmaceuticals, Inc....
Current EyePoint Pharmaceuticals, Inc. Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| RBC Capital |
Locked
➜
Locked
|
Locked | Jun 17 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | May 29 2025 |
| Mizuho |
Locked
➜
Locked
|
Locked | May 16 2025 |
| Chardan Capital |
Locked
➜
Locked
|
Locked | May 08 2025 |
| Chardan Capital |
Locked
➜
Locked
|
Locked | Mar 06 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Mar 06 2025 |
| Chardan Capital |
Locked
➜
Locked
|
Locked | Feb 06 2025 |
| Analyst Rating | Date |
|---|---|
|
Locked
RBC Capital:
Locked
➜
Locked
|
Jun 17 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
May 29 2025 |
|
Locked
Mizuho:
Locked
➜
Locked
|
May 16 2025 |
|
Locked
Chardan Capital:
Locked
➜
Locked
|
May 08 2025 |
|
Locked
Chardan Capital:
Locked
➜
Locked
|
Mar 06 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Mar 06 2025 |
|
Locked
Chardan Capital:
Locked
➜
Locked
|
Feb 06 2025 |
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
